The Gaucher Disease Type III drugs in development market research report provides comprehensive information on the therapeutics under development for Gaucher Disease Type III, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Gaucher Disease Type III. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Gaucher Disease Type III and features dormant and discontinued products.
GlobalData tracks eight drugs in development for Gaucher Disease Type III by six companies/universities/institutes. The top development phase for Gaucher Disease Type III is preclinical with three drugs in that stage. The Gaucher Disease Type III pipeline has eight drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Gaucher Disease Type III pipeline products market are: Sanofi, M6P Therapeutics and Shanghai Lingyi Biotechnology.
The key targets in the Gaucher Disease Type III pipeline products market include Lysosomal Acid Glucosylceramidase, and Ceramide Glucosyltransferase.
The key mechanisms of action in the Gaucher Disease Type III pipeline product include Ceramide Glucosyltransferase Inhibitor with three drugs in Phase III. The Gaucher Disease Type III pipeline products include two routes of administration with the top ROA being Oral and four key molecule types in the Gaucher Disease Type III pipeline products market including Gene Therapy, and Recombinant Enzyme.
Gaucher Disease Type III overview
Gaucher disease type III is the subacute neurological form of Gaucher disease characterized by progressive encephalopathy and associated with the systemic manifestations (organomegaly, bone involvement, cytopenia) of Gaucher disease type 1. It is caused by a mutation in the GBA gene (1q21) that codes for the lysosomal enzyme, glucocerebrosidase. The deficiency in glucocerebrosidase leads to the accumulation of glucosylceramidase (or beta-glucocerebrosidase) deposits in the cells of the reticuloendothelial system of the liver, spleen and the bone marrow (Gaucher cells)
For a complete picture of Gaucher Disease Type III’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
